Olympus and USC announce new partnership to advance cancer research

USC-Olympus Innovation Partnership in Multiscale Bioimaging aims to improve cancer detection, prevention, and management

The University of Southern California and Olympus have announced their first-ever co-development partnership with the goal of advancing multiscale research into cancer prevention, diagnosis, and treatment through precision medicine. The USC-Olympus Innovation Partnership in Multiscale Bioimaging demonstrates the clinical utility of new technologies that combine the workflow of a surgical biopsy and primary diagnosis with microscopic cellular and molecular characterization. The resulting personalized medicine and treatment selection will advance cancer research and potentially improve the precision of patient diagnosis and treatment.

Celebrating the launch of USC-Olympus Innovation Partnership.
Pictured from left to right: Dr. Scott Fraser, Director, USC Translational Imaging Center; Lee Wagstaff, VP, Olympus Corporation of the Americas Scientific Solutions Group; Dr. David Agus, Founding Director, Lawrence J. Ellison Institute for Transformative Medicine of USC; and David Rideout, ED of Marketing, Olympus Corporation of the Americas Scientific Solutions Group.

The new USC-Olympus Innovation Partnership in Multiscale Bioimaging combines Olympus technology with the expertise of two renowned, university-wide institutes at USC, the Lawrence J. Ellison Institute for Transformative Medicine and the Translational Imaging Center (TIC). The Ellison Institute, named after a $200 million donation by Oracle founder Larry Ellison, aims to change the way cancer is treated and prevented by driving transdisciplinary, patient-centered, and nimble research programs with great promise to shape clinical care. The Ellison Institute’s mission aligns with TIC's focus on advancing biological imaging for real-world impact, while Olympus provides innovative imaging technologies and healthcare solutions.

The partnership is guided by the scientific leadership of two internationally recognized leaders: trailblazing oncologist and biomedical entrepreneur David Agus, M.D., and world-leading optical and imaging researcher Scott Fraser, Ph.D. Together, with their respective teams, they are pioneering the development of new technologies to enable 3D and 4D imaging of single cells, organoids, and tumor ecosystems.

Cancer medicine is at a crossroads. Molecular research has shown that hundreds of genes and proteins are involved, making it difficult to envision how genetic approaches and standard treatments will cure cancer. Because of this, USC and Olympus have assembled a powerful team of translational researchers, clinicians and technologists to advance diagnostic capabilities toward precision medicine."

David Agus, M.D., oncologist and biomedical entrepreneur

Precision medicine takes into account a patient's tumor and immune-system profile and integrates this information with data from multiple sources—the patient's genes, environment and lifestyle. By analyzing patients’ data at the cellular and molecular levels, we begin to understand the tumor's behavior in its environment. A key aspect of the precision approach is tailoring treatment to the individual patient by performing high-content analysis on patient-derived samples treated with anti-cancer drugs. Patient-derived samples are grown into 3D tumor organoids in multi-well microplates to replicate the physiological conditions of the human immune system, providing significant advantages over traditional 2D cultures or slide samples, especially as drugs are tested on the organoids and measured over time.

The translation from the lab to the clinic is a complex process that can be elusive. USC continues to master "bench to bedside and back to bench" research and is a proven innovator in biologic imaging at multiple scales, especially in colorectal cancer.

Our partnership with Olympus is accelerating our capacities to develop and advance bioimaging technologies, helping us to create the next-generation tools needed to accelerate translational research and, ultimately, benefiting patients sooner and widening the horizons of multiscale imaging."

Professor Scott Fraser, Ph.D., optical and imaging researcher

Olympus is honored to provide the optical tools used to capture the breadth of what's happening in patients and transforming cancer medicine. Our deep experience and capabilities in both microscopy and medical technology businesses position us to lead the charge in the fight against cancer. We are excited to partner in the co-development of technology with the hope of translating these innovations to healthier, safer, and more fulfilling lives for people around the world."

Julien Sauvagnargues, President of Olympus Corporation of Americas Scientific Solutions Group

Life happens in 3D, and the USC-Olympus Innovation Partnership in Multiscale Bioimaging brings Olympus expertise in 3D imaging and our extensive track record in the GI space together with USC’s multidimensional approach to precision medicine. We couldn’t be more excited to be working with such visionaries in the fight against cancer.”

Randy Clark, President, Medical Systems Group, Olympus Corporation of the Americas


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation - Life Sciences. (2019, June 20). Olympus and USC announce new partnership to advance cancer research. News-Medical. Retrieved on July 13, 2024 from https://www.news-medical.net/news/20190109/Olympus-and-USC-announce-new-partnership-to-advance-cancer-research.aspx.

  • MLA

    Evident Corporation - Life Sciences. "Olympus and USC announce new partnership to advance cancer research". News-Medical. 13 July 2024. <https://www.news-medical.net/news/20190109/Olympus-and-USC-announce-new-partnership-to-advance-cancer-research.aspx>.

  • Chicago

    Evident Corporation - Life Sciences. "Olympus and USC announce new partnership to advance cancer research". News-Medical. https://www.news-medical.net/news/20190109/Olympus-and-USC-announce-new-partnership-to-advance-cancer-research.aspx. (accessed July 13, 2024).

  • Harvard

    Evident Corporation - Life Sciences. 2019. Olympus and USC announce new partnership to advance cancer research. News-Medical, viewed 13 July 2024, https://www.news-medical.net/news/20190109/Olympus-and-USC-announce-new-partnership-to-advance-cancer-research.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Olympus announces first results of its AI-based pathology diagnostic tool for gastric cancer